Tus Pharmaceutical Group Co Ltd (000590) - Total Liabilities
Based on the latest financial reports, Tus Pharmaceutical Group Co Ltd (000590) has total liabilities worth CN¥333.17 Million CNY (≈ $48.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Tus Pharmaceutical Group Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Tus Pharmaceutical Group Co Ltd - Total Liabilities Trend (1995–2025)
This chart illustrates how Tus Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Tus Pharmaceutical Group Co Ltd assets under control.
Tus Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tus Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hoasen Group
VN:HSG
|
Vietnam | ₫10.34 Trillion |
|
CapMan Oyj B
HE:CAPMAN
|
Finland | €155.63 Million |
|
LiveWire Group Inc.
NYSE:LVWR
|
USA | $99.31 Million |
|
Groenlandsbanken AS
CO:GRLA
|
Denmark | Dkr9.93 Billion |
|
KC Co. Ltd
KO:029460
|
Korea | ₩239.82 Billion |
|
Hangzhou Todaytec Digital Co Ltd Class A
SHE:300743
|
China | CN¥400.77 Million |
|
Crowell Development Corp
TW:2528
|
Taiwan | NT$14.14 Billion |
|
Aju IB Investment Co. Ltd
KQ:027360
|
Korea | ₩75.93 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Tus Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Tus Pharmaceutical Group Co Ltd (000590) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tus Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tus Pharmaceutical Group Co Ltd (1995–2025)
The table below shows the annual total liabilities of Tus Pharmaceutical Group Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥339.98 Million ≈ $49.75 Million |
-17.52% |
| 2024-12-31 | CN¥412.18 Million ≈ $60.32 Million |
-2.54% |
| 2023-12-31 | CN¥422.92 Million ≈ $61.89 Million |
-8.90% |
| 2022-12-31 | CN¥464.26 Million ≈ $67.94 Million |
+62.61% |
| 2021-12-31 | CN¥285.50 Million ≈ $41.78 Million |
+15.46% |
| 2020-12-31 | CN¥247.27 Million ≈ $36.18 Million |
+10.10% |
| 2019-12-31 | CN¥224.58 Million ≈ $32.86 Million |
-5.19% |
| 2018-12-31 | CN¥236.88 Million ≈ $34.66 Million |
-18.43% |
| 2017-12-31 | CN¥290.40 Million ≈ $42.50 Million |
-20.81% |
| 2016-12-31 | CN¥366.72 Million ≈ $53.66 Million |
-3.91% |
| 2015-12-31 | CN¥381.64 Million ≈ $55.85 Million |
-5.23% |
| 2014-12-31 | CN¥402.71 Million ≈ $58.93 Million |
+42.28% |
| 2013-12-31 | CN¥283.05 Million ≈ $41.42 Million |
+25.56% |
| 2012-12-31 | CN¥225.44 Million ≈ $32.99 Million |
-10.41% |
| 2011-12-31 | CN¥251.62 Million ≈ $36.82 Million |
-13.19% |
| 2010-12-31 | CN¥289.85 Million ≈ $42.41 Million |
+1.66% |
| 2009-12-31 | CN¥285.11 Million ≈ $41.72 Million |
+14.72% |
| 2008-12-31 | CN¥248.53 Million ≈ $36.37 Million |
+2.97% |
| 2007-12-31 | CN¥241.37 Million ≈ $35.32 Million |
-11.94% |
| 2006-12-31 | CN¥274.10 Million ≈ $40.11 Million |
-30.79% |
| 2005-12-31 | CN¥396.04 Million ≈ $57.95 Million |
-3.18% |
| 2004-12-31 | CN¥409.06 Million ≈ $59.86 Million |
-3.98% |
| 2003-12-31 | CN¥426.00 Million ≈ $62.34 Million |
-4.04% |
| 2002-12-31 | CN¥443.96 Million ≈ $64.96 Million |
+6.62% |
| 2001-12-31 | CN¥416.40 Million ≈ $60.93 Million |
+62.51% |
| 2000-12-31 | CN¥256.24 Million ≈ $37.50 Million |
+2.88% |
| 1999-12-31 | CN¥249.06 Million ≈ $36.45 Million |
+83.72% |
| 1998-12-31 | CN¥135.56 Million ≈ $19.84 Million |
+2.52% |
| 1997-12-31 | CN¥132.23 Million ≈ $19.35 Million |
+190.34% |
| 1996-12-31 | CN¥45.54 Million ≈ $6.66 Million |
-39.87% |
| 1995-12-31 | CN¥75.74 Million ≈ $11.08 Million |
-- |
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offer… Read more